Copaxone PEN from Teva
Copaxone PEN

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed’s autoinjector YpsoMate®.

Ypsomed Headquarters in Burgdorf (Switzerland)

Press Releases Ypsomed Group

Burgdorf – No agreement has been reached between Ypsomed and Insulet Corp., its former supplier of Omnipod® devices on the amount of the expiration fee payable to Ypsomed under the terms of the distribution agreement that expired in June 2018. After unsuccessful attempts to amicably agree on the amount, Ypsomed has decided to file for arbitration. Ypsomed continues to estimate the expiration fee to amount to approximately CHF 50 million.